Decipher Biosciences Inc.
- Home
- Companies
- Decipher Biosciences Inc.
- Services
- Prostate Cancer Treatment
Prostate Cancer Treatment
Using Decipher genomic testing to determine where a patient is within the spectrum of risk empowers you in personalizing patient management
Most popular related searches
prostate cancer
prostate cancer patient
prostate cancer treatment
gleason score
prostate
immune activating
immune activity
immune activation
genomic test
genomic tested
AFTER BIOPSY
- ALL Gleason Scores
- ALL PSA Values
- ALL Stages
AFTER RADICAL PROSTATECTOMY
- ALL Gleason Scores
- ALL PSA Values (including undetectable, rising, and persistently elevated PSA)
- ALL Stages
Decipher Prostate is indicated for non-metastatic men who have not received pelvic radiation or ADT prior to biopsy or RP and have a life expectancy of 10 years or greater.
Decipher Prostate Covers 7 Cancer Pathways
- Invasion & Metastasis
- Androgen Signoling
- Metabolism
- Angiogenesis
- Growth & Differentiation
- Proliferation & Cell Death
- Immune Activity & Response
Decipher Prostate was developed from a large cohort of metastatic and non-metastatic prostate cancer patients treated at the Mayo Clinic. The whole transcriptome test utilizes 22 coding and non-coding biomarkers that span seven cancer pathways to provide a more accurate, independent prediction of risk.